Efficacy of preventive human papillomavirus vaccination

International Journal of STD and AIDS

Volumn 12, Issue 12, 2001, Pages 771-776

  Lehtinen, M ^a   Paavonen, J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cervical cancer; Human papillomavirus; Vaccine

Indexed keywords

PROTEIN E; PROTEIN L; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

GENE EXPRESSION; HLA SYSTEM; IMMUNE SYSTEM; NONHUMAN; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX TUMOR; VACCINATION; VIRUS GENE; VIRUS INFECTION; WART VIRUS;

ANIMALS; CANCER VACCINES; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIRAL VACCINES;

EID: 0035204744     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462011924317     Document Type: Review

References (80)

1. Papillomaviruses
2. New HPV E6 binding proteins: Dangerous liaisions
3. Papillomaviruses in human cancers
4. Human papillomaviruses
5. Human papillomavirus and cancer: The epidemiologic evidence
6. Human papillomavirus infection, risk for subsequent development of cervical carcinoma and asssociated preventable population attributable fraction
7. Trends in mortality from cervical cancer in the Nordic countries: Association with organised screening programmes
8. Prospects for phase III-IV HPV vaccination trials in the Nordic countries and in Estonia
9. No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11
10. Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis
11. Prospective seroepidemiological study on human papillomavirus type 16, 18 and 33 and non-cervical anogenital cancers
12. A prospective study of human papillomavirus infection as a risk factor for head and neck cancer
13. A prospective study of the role of human papillomavirus in esophageal cancer in Norway
14. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis
15. Interlaboratory aggreement among results of human papillomavirus type 16 enzyme-linked immunosorbent assays
16. Identification of human papillomavirus seroconversions
17. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: A population-based case-control study
18. Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses folloowing incident infection
19. Immunoglobulin G responses against human papillomavirus type 16 virus like particles in a prospective non-intervention cohort study of women with cervical intraepithelial neoplasia
20. Stability over time of serum antibody levels to human papillomavirus type 16
21. Divergent human papillomavirus type 16 variants are serologically cross-reactive
22. Developing HPV virus like particle vaccines to prevent cervical cancer: A progress report
23. Common neutralization epitopes in minor capsid protein L2 of human papillomavirus types 16 and 6
24. Pre- and post-treatment serum antibody responses to HPV16 E2 and HSV2 ICP8 proteins in women with cervical carcinoma
25. Disappearence of antibodies to HPV16 E7 after treatment for cervical cancer
26. Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carcinoma of the uterine cervix
27. Human papillomavirus DNA and antibodies to human papillomavirus 16 E2, L2 and E7 peptides as predictors of survival in patients with squamous cell cervical cancer
28. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer
29. Antibodies against oncoproteins E6 and E7 of human papillomavirus type 16 and 18 in cervical carcinoma patients from Russia
30. Human papillomavirus associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome
31. Human T cell responses to human papillomavirus type 16 L1 and E6 synthetic peptides: Identification of T cell determinants, HLA-DR restriction and virus type specificity
32. Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma in healthy individuals
33. Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia
34. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: Correlation with cervical pathology
35. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: A longitudinal study
36. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III
37. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymfocytes
38. Loss of transporter protein, encoded by the TAP-1 gene is highly correlated with loss of HLA expression in cervical carcinoma
39. Immunity to human papillomavirus-associated cervical neoplasia
40. Human papillomavirus type 16 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles
41. HLA class II antigen expression in human papillomavirus associated cervical cancer
42. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer
43. Serotypes of Chlamydia trachomatis and the risk to develop cervical squamous cell carcinoma
44. Chlamydial pelvic inflammatory disease
45. Familial risks in cervical cancer: Is there a hereditary component
46. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3
47. Analysis of E2 amino acid variants of human papillomavirus types 16 and 18 and their associations with lesion grade and HLA DR/DQ type
48. HPV16 infection and progresion of cervical intraepithelial neoplasia: Analysis of HLA polymorphism and HPV16 E6 sequence variants
49. HPV typing and HPV16 E6-sequence variations in synchronous lesions of cervical squamous cell carcinoma from Swedish patients
50. Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment
51. A recombinant vaccinia virus encoding human papilloma virus types 16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer
52. Cell-mediated immunological responses in cervical and vaginal carcinoma patients immunized with a lipidated epitope of human papillomavirus type 16 E7
53. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma. Clinical evaluation of a phase I-II trial
54. Putative immunodominant human immunodeficiency virus-specific CD8+ T-cell responses cannot be predicted by major histocompatibility complex class I haplotype
55. Human T helper cell epitopes overlap B cell and putative cytotoxic T cell epitopes in the E2 protein of human papillomavirus type 16
56. Identification of a cytotoxic T lymphocyte epitope in the human papillomavirus 16 E2 protein
57. Development of hepatitis B vaccine from transformed yeast cells
58. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - Results of a 10-year study
59. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type
60. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: A nested case-control study
61. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles
62. Nasal immunization of mice with human papillomavirus types 16 (HPV16) virus like particles or with HPV16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes
63. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
64. Vaccination with yeast expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation
65. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization
66. Natural HPV immunity and vaccination strategies
67. Chimeric papillomavirus like particles
68. Papillomavirus virus like particles can deliver CTL epitopes to the MHC class I pathway
69. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus proteins
70. Lack of immortalization activity of a human papillomavirus type 16 variant DNA with a mutation in the E2 gene isolated from normal human cervical keratinocytes
71. Human papillomavirus type 6: Classification of clinical isolates and functional analysis of E2 proteins
72. Human papillomavirus and disease free survival in FIGO stage Ib cervical cancer
73. Sequence variations and viral genomic state of human papillomavirus type 16 in penile carcinomas from Ugandan patients
74. Association of human papillomavirus type 16 integration in the E2 gene with poor disease free survival from cervical cancer
75. Immunization with non-structural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas
76. Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus E1, E2, E6 and E7 genes
77. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles; induction of cytotoxic T cells and specific tumor protection
78. Overview of vacinology with special reference to papillomavirus vaccines
79. The role of vaccines in the control of STDs: HPV vaccines
80. Vaccinating women against premature death